Literature DB >> 8055847

An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990.

M R Law1, N J Wald.   

Abstract

OBJECTIVE: (i) To carry out a quantitative analysis of the average serum cholesterol levels in different countries in relationship to the ischaemic heart disease (IHD) mortality in these countries. (ii) To examine changes in serum cholesterol levels over time in different countries.
DESIGN: Analysis of published surveys measuring average serum cholesterol in specified communities in different countries.
SETTING: The original cholesterol surveys were mainly in occupational and residential settings.
RESULTS: Survey data allowed estimation of average serum cholesterol levels during specified time periods for 17 countries; estimates in men aged 40-59 years varied from 3.8 mmol/l (rural China) to 7.0 mmol/l (Finland). Variation in serum cholesterol accounted for 80% of the tenfold range in risk of IHD across countries. A difference in total (or LDL) cholesterol of 0.6 mmol/l between countries was associated with an average difference in IHD mortality of 37% at age 55-64 years. Repeat surveys showed that serum cholesterol reductions of the order of 0.6 mmol/l have occurred in some communities over about 5-10 years.
CONCLUSIONS: Variation in serum cholesterol explains four-fifths of the geographical variation in IHD mortality. Reductions in cholesterol of about 0.6 mmol/l (10%) have been achieved in some Western communities or countries over periods of a few years, a change that is associated with a decrease in IHD mortality of over one-third.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8055847

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  14 in total

1.  Plant sterol and stanol margarines and health.

Authors:  M Law
Journal:  BMJ       Date:  2000-03-25

2.  Why heart disease mortality is low in France: the time lag explanation.

Authors:  M Law; N Wald
Journal:  BMJ       Date:  1999-05-29

Review 3.  Risk factor thresholds: their existence under scrutiny.

Authors:  M R Law; N J Wald
Journal:  BMJ       Date:  2002-06-29

4.  [Prevention of disability in the elderly].

Authors:  H P Thomas; E Steinhagen-Thiessen
Journal:  Internist (Berl)       Date:  2004-02       Impact factor: 0.743

Review 5.  Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.

Authors:  Robert A Hegele; Samuel S Gidding; Henry N Ginsberg; Ruth McPherson; Frederick J Raal; Daniel J Rader; Jennifer G Robinson; Francine K Welty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09-16       Impact factor: 8.311

6.  A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women.

Authors:  Viktor Hamrefors; Marju Orho-Melander; Ronald M Krauss; Bo Hedblad; Peter Almgren; Göran Berglund; Olle Melander
Journal:  J Lipid Res       Date:  2009-09-22       Impact factor: 5.922

7.  Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.

Authors:  Jian-Jun Ou; Yi Xu; Hong-Hui Chen; Xiaoduo Fan; Keming Gao; Juan Wang; Xiao-Feng Guo; Ren-Rong Wu; Jing-Ping Zhao
Journal:  Psychopharmacology (Berl)       Date:  2012-08-28       Impact factor: 4.530

8.  CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia.

Authors:  F Raal; C Schamroth; D Blom; J Marx; M Rajput; M Haus; R Hussain; F Cassim; M Nortjé; G Vandehoven; A-M Temmerman
Journal:  Cardiovasc J Afr       Date:  2011-09-15       Impact factor: 1.167

Review 9.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006

10.  Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction.

Authors:  Lena Björck; Catharina Welin; Annika Rosengren
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.